Particularly, antileukemic activity of pyrvinium was observed in pediatric MLL-rearranged AML, B-cell acute lymphoblastic leukemia (ALL), and T-ALL with NOTCH inactivation signature [58–60]. Here, KMT2A is linked to acute lymphoblastic leukemia.